•  
  •  
 

Indonesian Journal of Medical Chemistry and Bioinformatics

Abstract

COVID-19, caused by SARS-CoV-2 has been reported to be associated with coagulopathy and DIC. This study aimed to investigate the profiles and differences of PT, APTT, fibrinogen, and D-dimer in COVID- 19 outcome. This retrospective cohort was conducted at Central Laboratory Clinical Pathology Department of dr. Cipto Mangunkusumo Hospital from July – December 2020. Demographic, clinical, and laboratory data were extracted from EHR and compared between poor and good outcome. Ninety-seven subjects were confirmed positive COVID-19, 45 of whom (46.4%) were in poor outcome group, while 52 subjects (53.6%) were in good outcome group. Median of PT 11.0” (9.7-28.3), APTT 38.4” (23.9-121), fibrinogen 484.8 mg/dL (51.2-940.9), and D-dimer 1,800 µg/L (190-35,200). Longer PT, APTT, and higher D-dimer (p < 0.05), while lower fibrinogen (p > 0.05) was found in poor outcome group. There were significant differences of PT, APTT and D-dimer in COVID-19 outcome.

Bahasa Abstract

COVID-19, yang disebabkan oleh SARS-CoV-2 telah dilaporkan berkaitan dengan koagulopati dan DIC. Penelitian ini bertujuan untuk mengetahui profil dan perbedaan PT, APTT, fibrinogen, dan D-dimer sebagai efek dari COVID-19. Penelitian kohort retrospektif ini dilakukan di Laboratorium Pusat Departemen Patologi Klinik RS Cipto Mangunkusumo periode Juli – Desember 2020. Data demografi, klinis, dan laboratorium diambil dari EHR yang kemudian dibandingkan antara hasil yang buruk dan baik. Sembilan puluh tujuh subjek terkonfirmasi positif COVID-19, 45 di antaranya (46,4%) berada pada kelompok hasil buruk, sedangkan 52 subjek (53,6%) berada pada kelompok hasil baik. Nilai median dari PT 11.0” (9.7-28.3), APTT 38.4” (23.9-121), fibrinogen 484.8 mg/dL (51.2-940.9), dan D-dimer 1,800 µg/L (190-35,200). PT, APTT, dan D-dimer yang lebih panjang (p0,05) ditemukan pada kelompok hasil yang buruk. Terdapat perbedaan yang signifikan antara PT, APTT dan D-dimer terhadap outcome COVID-19.

References

  1. He, F.; Deng, Y.; Li, W. Coronavirus disease 2019: What we know?. J Med Virol, 2020, 92(7):719–25.
  2. Huang, C.; Wang, Y.; Li, X.; Ren, L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497–506.
  3. Chakraborty, C.; Sharma, A.R.; Sharma, G.; Bhattacharya, M.; Lee, S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options. Eur Rev Med Pharmacol Sci, 2020, 24(7): 4016–26.
  4. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost, 2020, 18(4): 844–7.
  5. Wang, L.; He, W.B..; Yu, X.M.; Hu, D.L.; Jiang, H. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID- 19 patients. World J Clin Cases, 2020, 8(19): 4370–9.
  6. Burhan, E.; Susanto, A.D.; Nasution, S.A.; Ginanjar, E.; Pitoyo, C.W.; Susilo, A.; et al. PEDOMAN TATALAKSANA COVID-19 Edisi 3 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terap. Indonesia, 2020. 3–6, 88– 89 p.
  7. Lukito, A.A.; Harmeiwaty, E.; Hustrini, N.M.; editors. Konsensus Penatalaksanaan Hipertensi 2019 [Internet]. Perhimpunan Dokter Hipertensi Indonesia: Indonesia, 2019.
  8. Soelistijo, S.A.; Lindarto, D.; Decroli, E.; Permana, H.; Sucipto, K.W.; Kusnadi, Y. et al. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2019. PB Perkeni : Indonesia, 2019.
  9. Kementerian Kesehatan RI. Epidemi Obesitas. Jurnal Kesehatan, 2018. p. 1–8. Available from: http://www.p2ptm.kemkes.go.id/dokumen-ptm/factsheet-obesitas-kit-informasi- obesitas
  10. Jin, J.M.; Bai, P.; He, W.; Wu, F.; Liu, X.F.; Han, D.M. et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. Front Public Heal, 2020, 8(April): 1–6.
  11. Karyono, D.R.; Wicaksana, A.L. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empower Heal, 2020, 3(2): 77.
  12. de Terwangne, C.; Laouni, J.; Jouffe, L.; Lechien, J.R.; Bouillon, V.; Place, S. et al. Predictive accuracy of covid-19 world health organization (Who) severity classification and comparison with a bayesian-method-based severity score (epi-score). Pathogens, 2020, 9(11):1–17.
  13. Yang, J.; Zheng, Y.; Gou, X.; Pu, K.; Chen, Z.; Guo, Q. et al. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta- analysis. Int J Infect Dis, 2020, 94: 91–5.
  14. Sattar, N.; McInnes, I.B.; McMurray, J.J.V. Obesity is a risk factor for severe COVID-19 infection: Multiple potential mechanisms. Circulation, 2020, 4–6.
  15. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020, 395(10229): 1054–62. Available from: http://dx.doi.org/10.1016/S0140- 6736(20)30566-3
  16. Willim, H.A.; Hardigaloeh, A.T.; Supit, A.I. Koagulopati pada coronavirus disease - 2019 ( COVID-19 ): Tinjauan pustaka. Intisari Sains Medis, 2020, 11(3): 749–56.
  17. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - J Am Med Assoc, 2020, 323(11): 1061–9.
  18. Zhai, W.; Luo, Z.; Zheng, Y.; Dong, D.; Wu, E.; Wang, Z. et al. Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study. Sci Rep, 2021, 11(1): 1–11. Available from: https://doi.org/10.1038/s41598-021- 85869-0
  19. Salabei, J.K.; Fishman, T.J.; Asnake, Z.T.; Ali, A.; Iyer, U.G. Covid-19 coagulopathy: current knowledge and guidelines on anticoagulation. Hear Lung, 2021, 50(2): 357–60. Available from: https://doi.org/10.1016/j.hrtlng.2021.01.0 11

Download

Share

COinS